Although we found a few small lesions that lost the expression of HLA and B2M in the relapsed tumor from JFCR-119 (Fig. S1 D), both HLA and B2M were widely positive in the pretreatment tumor and in the majority of post-treatment tumor lesions (Fig. S1, D and E). This evidence concerns the gene B2M and neoplasm.